These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34378323)

  • 21. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
    Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
    Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insulin growth factor binding protein 2 mediates the progression of lymphangioleiomyomatosis.
    Li X; Liu X; Zhang L; Li C; Zhang E; Ma W; Fan Q; Yu JJ
    Oncotarget; 2017 May; 8(22):36628-36638. PubMed ID: 28410230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
    Amaral AF; de Oliveira MR; Dias OM; Arimura FE; Freitas CSG; Acencio MMP; de Alvarenga VA; Kairalla RA; Carvalho CRR; Baldi BG;
    Lung; 2019 Apr; 197(2):139-146. PubMed ID: 30623243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response.
    Miller S; Stewart ID; Clements D; Soomro I; Babaei-Jadidi R; Johnson SR
    J Pathol Clin Res; 2020 Jul; 6(3):215-226. PubMed ID: 32352655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.
    Ito T; Suno M; Sakamoto K; Yoshizaki Y; Yamamoto K; Nakanishi R; Hirano Y; Irie M; Kurosaki T; Otani S; Yamane M; Sugimoto S; Miyoshi K; Oto T
    Transplant Proc; 2016; 48(1):271-4. PubMed ID: 26915883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphangioleiomyomatosis.
    Doubková M; Štefániková M; Čan V; Merta Z; Svoboda M
    Klin Onkol; 2019; 32(5):367-374. PubMed ID: 31610670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM).
    Trindade AJ; Medvetz DA; Neuman NA; Myachina F; Yu J; Priolo C; Henske EP
    PLoS One; 2013; 8(3):e60014. PubMed ID: 23555865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.
    Kim C; Do KH; Cha J; Song JW; Lee SM; Lee KY
    Eur Radiol; 2020 Feb; 30(2):735-743. PubMed ID: 31471750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of beta-agonists on LAM progression and treatment.
    Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis.
    Glasgow CG; Pacheco-Rodriguez G; Steagall WK; Haughey ME; Julien-Williams PA; Stylianou MP; Gochuico BR; Moss J
    Chest; 2018 Feb; 153(2):339-348. PubMed ID: 28576630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
    McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ;
    N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mast-Cell Tryptase Release Contributes to Disease Progression in Lymphangioleiomyomatosis.
    Babaei-Jadidi R; Dongre A; Miller S; Castellanos Uribe M; Stewart ID; Thompson ZM; Nateri AS; Bradding P; May ST; Clements D; Johnson SR
    Am J Respir Crit Care Med; 2021 Aug; 204(4):431-444. PubMed ID: 33882264
    [No Abstract]   [Full Text] [Related]  

  • 34. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
    Yu J; Parkhitko AA; Henske EP
    Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in the pathobiology and clinical management of lymphangioleiomyomatosis.
    Harari S; Spagnolo P; Cocconcelli E; Luisi F; Cottin V
    Curr Opin Pulm Med; 2018 Sep; 24(5):469-476. PubMed ID: 29927757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR signaling in lymphangioleiomyomatosis.
    Kristof AS
    Lymphat Res Biol; 2010 Mar; 8(1):33-42. PubMed ID: 20235885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.
    Kristof AS; You Z; Han YS; Giaid A
    Peptides; 2010 Aug; 31(8):1511-6. PubMed ID: 20433884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.
    Hecimovic A; Jakopovic M; Pavlisa G; Jankovic M; Vukic-Dugac A; Redzepi G; Brcic L; Samarzija M; Gupta N
    Lymphology; 2015 Jun; 48(2):97-102. PubMed ID: 26714374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glutaredoxin-1 promotes lymphangioleiomyomatosis progression through inhibiting Bim-mediated apoptosis via COX2/PGE2/ERK pathway.
    Feng Y; Li T; Li Y; Lin Z; Han X; Pei X; Zhang Y; Li F; Yang J; Shao D; Li C
    Clin Transl Med; 2023 Jul; 13(7):e1333. PubMed ID: 37478294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.